XNAS
TRUG
Market cap11mUSD
Oct 08, Last price
2.56USD
1D
-6.91%
1Q
-80.16%
IPO
-99.74%
Name
Deep Medicine Acquisition Corp
Chart & performance
P/E
—
P/S
0.59
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
19m
-13.63%
Net income
-15m
L+73.13%
CFO
-2m
L-57.49%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Deep Medicine Acquisition Corp. (DMAQ) currently operates as a non-operating entity, possessing no substantial business functions of its own. Its express purpose is to execute a business combination, which could entail a merger, an acquisition of equity or assets, or a reorganization, with one or more target companies. The firm's strategic efforts are specifically concentrated on identifying promising enterprises within the healthcare industry. Incorporated in 2020, DMAQ maintains its principal place of business in New York, New York.
Key people
Shaun Limbers
Executive Vice President, Director · since 2024
Brenner Adams
Chief Growth Officer · since 2022
Steven Johnson
Chief Hardware Officer
Nathan Larsen
Chief Experience Officer · since 2021
Christopher Jones
Chairman of the Board, President, Chief Executive Officer · since 2024
Humphrey Polanen
Independent Director · since 2024
A. J. Redmer
Independent Director · since 2024
Riley Russell
Independent Director · since 2024
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑12 | 2025‑03 | 2024‑12 | 2023‑03 | 2022‑03 | 2021‑03 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||